Okeanis Eco Tankers Corp. (ECO)

NYQ – Real vaqt narxi. Valyuta: USD

56.65

+0.72 (1.29%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13 Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conference SAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation of VK2735 at the European Congress on Obesity (ECO) in Istanbul, Türkiye. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development with subcutaneous and oral formulations for the potential treatment of various metabolic disorders.

08.05.2026

Okeanis Eco Tankers Corp. – Invitation to Q1 2026 Results Webcast

ATHENS, Greece, May 08, 2026 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (the “Company” or “OET”) (NYSE:ECO / OSE:OET), will report unaudited condensed financial results for the first quarter of 2026, after market close on the NYSE, on Wednesday, May 13, 2026, and a webcast will be held at 14:30 CET, on Thursday, May 14, 2026.

05.05.2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.

04.05.2026

Okeanis Eco Tankers Corp. – New Financings Update

ATHENS, Greece, May 04, 2026 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (the “Company” or “OET”) (NYSE:ECO / OSE:OET), announced today that it has entered into three new loan facility agreements.

24.04.2026

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

ATHENS, Greece, April 24, 2026 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (the “Company” or “OET”) (NYSE:ECO / OSE:OET), announced today that it has scheduled its Annual Meeting of Shareholders for May 29, 2026, at 11:00 a.m. Greek time (the “Annual Meeting”). The record date for determining shareholders entitled to participate at the Annual Meeting is April 21, 2026. The business of the Annual Meeting is to elect eight directors to serve until the next annual meeting of shareholders and until their successors are elected and qualified, and to ratify the appointment of Deloitte Certified Public Accountants S.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Annual Meeting documentation and instructions for voting are expected to be mailed to all shareholders of record on or about April 24, 2026, and will be furnished to the U.S. Securities and Exchange Commission (the “Commission”) and available on the Commission's website at www.sec.gov.

20.04.2026

Okeanis Eco Tankers Corp. (ECO) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Okeanis Eco Tankers Corp. (ECO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

20.04.2026

Okeanis: Iran Disruption And The Road To A 30%+ Dividend Yield (Rating Upgrade)

Okeanis Eco Tankers is upgraded to buy, driven by a modern fleet, spot market exposure, and robust earnings outlook. ECO's Q2 results are expected to be extraordinary, with guidance around $200,000/day and significant Venezuelan cargo premiums. Valuation remains compelling: trading at ~1.1x NAV, with a fair value estimate of $60/share and a potential 40% annualized yield.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

05.05.2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

04.05.2026

Okeanis Eco Tankers Corp. – New Financings Update

24.04.2026

Okeanis Eco Tankers Corp. (ECO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Okeanis Eco Tankers Corp. (ECO)

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – Invitation to Q1 2026 Results Webcast

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

Okeanis Eco Tankers Corp. (ECO) is on the Move, Here's Why the Trend Could be Sustainable

Okeanis: Iran Disruption And The Road To A 30%+ Dividend Yield (Rating Upgrade)

Videolar

No Data

Press-relizlar

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – Invitation to Q1 2026 Results Webcast

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

Okeanis Eco Tankers Corp. (ECO) is on the Move, Here's Why the Trend Could be Sustainable

Okeanis: Iran Disruption And The Road To A 30%+ Dividend Yield (Rating Upgrade)

Videolar

No Data

Press-relizlar

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

Search stocks

Okeanis Eco Tankers Corp. (ECO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Okeanis Eco Tankers Corp. (ECO)

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – Invitation to Q1 2026 Results Webcast

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

Okeanis Eco Tankers Corp. (ECO) is on the Move, Here's Why the Trend Could be Sustainable

Okeanis: Iran Disruption And The Road To A 30%+ Dividend Yield (Rating Upgrade)

Videolar

No Data

Press-relizlar

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – Invitation to Q1 2026 Results Webcast

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders

Okeanis Eco Tankers Corp. (ECO) is on the Move, Here's Why the Trend Could be Sustainable

Okeanis: Iran Disruption And The Road To A 30%+ Dividend Yield (Rating Upgrade)

Videolar

No Data

Press-relizlar

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Okeanis Eco Tankers Corp. – New Financings Update

Okeanis Eco Tankers Corp. – Announcement of 2026 Annual Meeting of Shareholders